loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for GW282974X

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    GW282974X

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,937Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
    FDA Grants Orphan Drug Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

    31 Aug 2022

    // PRESS RELEASE

    https://ir.biocryst.com/news-releases/news-release-details/fda-grants-orphan-drug-designation-biocrysts-alk-2-inhibitor

    PRESS RELEASE
    31 Aug 2022
    Share Share
    Enhertu strikes again with a PhIII success in another breast cancer population
    Enhertu strikes again with a PhIII success in another breast cancer population

    16 Aug 2022

    // Kyle LaHucik ENDPTS

    https://endpts.com/enhertu-strikes-again-with-a-phiii-success-in-another-breast-cancer-population/

    Kyle LaHucik ENDPTS
    16 Aug 2022
    Share Share
    Natco Pharma Ltd's Generic Lapatinib Ditosylate Receives Approval In US
    Natco Pharma Ltd's Generic Lapatinib Ditosylate Receives Approval In US

    29 Sep 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203007

    FDA
    29 Sep 2020
    Share Share
    No change to product information for breast cancer medicine Tyverb
    No change to product information for breast cancer medicine Tyverb

    27 Mar 2020

    // EMA

    https://www.ema.europa.eu/en/news/no-change-product-information-breast-cancer-medicine-tyverb-following-re-assessment-data

    EMA
    27 Mar 2020
    Share Share
    Puma Biotech cancer launch Nerlynx suffered in Q1.
    Puma Biotech cancer launch Nerlynx suffered in Q1.

    10 May 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/puma-biotech-s-nerlynx-suffers-a-terrible-quarter-what-gives

    Angus Liu FIERCE PHARMA
    10 May 2019
    Share Share
    Re-analysis of data on use of breast cancer, Tyverb treatment with trastuzumab
    Re-analysis of data on use of breast cancer, Tyverb treatment with trastuzumab

    30 Apr 2019

    // EMA

    https://www.ema.europa.eu/en/news/re-analysis-data-use-breast-cancer-medicine-tyverb-following-treatment-trastuzumab

    EMA
    30 Apr 2019
    Share Share